<DOC>
	<DOCNO>NCT00430846</DOCNO>
	<brief_summary>Phase I study define safety profile pharmacokinetic parameter SGN-35 patient relapsed/refractory CD30-positive hematologic malignancy . This single-arm , open-label , Phase I dose escalation study design define MTD , PK , immunogenicity anti-tumor activity SGN-35 patient relapsed/refractory CD30-positive hematologic malignancy .</brief_summary>
	<brief_title>Phase I Open-Label Dose Finding Study SGN-35 CD30 Positive Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients must histologically confirm CD30positive hematologic malignancy . Patients HL must fail systemic chemotherapy either induction therapy advance stage disease salvage therapy initial radiotherapy early stage disease ineligible , refuse treatment , previously receive stem cell transplant . Patients must measurable disease least 10mm documented radiographic technique . Must least 18 year age . Patients current diagnosis pcALCL ( systemic ALCL eligible ) . Patients history allogeneic stem cell transplant . Patients previous treatment antiCD30 antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Disease , Hodgkin</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
</DOC>